Two days ago GSK canned lete-cel. Now it is ditching otilimab, and daprodustat’s future is looking dicey.
Graduate 1 and 2 data are “not yet in house”, but a pooled analysis beckons in the event of one study failing.
Eisai is rewarded for doubling down on lecanemab with an apparent win that endorses 20 years of research.
The serial acquirer of royalty interests is coming into its own, but the secret to its success lies in cystic fibrosis.
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Biopharma takeouts in the $1-5bn range jumped in 2021, as rising valuations made their mark.
Small and mid-sized developers upped deal-making activity last year, a deep dive into M&A data finds.